199 related articles for article (PubMed ID: 34215653)
1. Proteolysis-Targeting Chimeras Enhance T Cell Bispecific Antibody-Driven T Cell Activation and Effector Function through Increased MHC Class I Antigen Presentation in Cancer Cells.
Massafra V; Tundo S; Dietzig A; Ducret A; Jost C; Klein C; Kontermann RE; Knoetgen H; Steegmaier M; Romagnani A; Nagel YA
J Immunol; 2021 Jul; 207(2):493-504. PubMed ID: 34215653
[TBL] [Abstract][Full Text] [Related]
2. A New Class of Bifunctional Major Histocompatibility Class I Antibody Fusion Molecules to Redirect CD8 T Cells.
Schmittnaegel M; Hoffmann E; Imhof-Jung S; Fischer C; Drabner G; Georges G; Klein C; Knoetgen H
Mol Cancer Ther; 2016 Sep; 15(9):2130-42. PubMed ID: 27353170
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses.
Nouri-Shirazi M; Banchereau J; Bell D; Burkeholder S; Kraus ET; Davoust J; Palucka KA
J Immunol; 2000 Oct; 165(7):3797-803. PubMed ID: 11034385
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response.
Kissick HT; Sanda MG; Dunn LK; Arredouani MS
PLoS One; 2014; 9(4):e93231. PubMed ID: 24690990
[TBL] [Abstract][Full Text] [Related]
5. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
Jaigirdar A; Rosenberg SA; Parkhurst M
J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
[TBL] [Abstract][Full Text] [Related]
6. Activation of human CD8+ alpha beta TCR+ cells by Mycobacterium tuberculosis via an alternate class I MHC antigen-processing pathway.
Canaday DH; Ziebold C; Noss EH; Chervenak KA; Harding CV; Boom WH
J Immunol; 1999 Jan; 162(1):372-9. PubMed ID: 9886409
[TBL] [Abstract][Full Text] [Related]
7. Recognition of a shared human prostate cancer-associated antigen by nonclassical MHC-restricted CD8+ T cells.
Housseau F; Bright RK; Simonis T; Nishimura MI; Topalian SL
J Immunol; 1999 Dec; 163(11):6330-7. PubMed ID: 10570328
[TBL] [Abstract][Full Text] [Related]
8. ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers.
Sinnathamby G; Zerfass J; Hafner J; Block P; Nickens Z; Hobeika A; Secord AA; Lyerly HK; Morse MA; Philip R
Clin Exp Immunol; 2011 Mar; 163(3):324-32. PubMed ID: 21175594
[TBL] [Abstract][Full Text] [Related]
9. CAR-J cells for antibody discovery and lead optimization of TCR-like immunoglobulins.
Jost C; Darowski D; Challier J; Pulko V; Hanisch LJ; Xu W; Mössner E; Bujotzek A; Klostermann S; Umana P; Kontermann RE; Klein C
MAbs; 2020; 12(1):1840709. PubMed ID: 33136521
[TBL] [Abstract][Full Text] [Related]
10. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
Front Immunol; 2019; 10():1505. PubMed ID: 31333652
[TBL] [Abstract][Full Text] [Related]
11. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
Denkberg G; Reiter Y
Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
[TBL] [Abstract][Full Text] [Related]
12. Cancer associated aberrant protein O-glycosylation can modify antigen processing and immune response.
Madsen CB; Petersen C; Lavrsen K; Harndahl M; Buus S; Clausen H; Pedersen AE; Wandall HH
PLoS One; 2012; 7(11):e50139. PubMed ID: 23189185
[TBL] [Abstract][Full Text] [Related]
13. Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells.
Matsuzaki J; Tsuji T; Luescher I; Old LJ; Shrikant P; Gnjatic S; Odunsi K
Cancer Immunol Res; 2014 Apr; 2(4):341-50. PubMed ID: 24764581
[TBL] [Abstract][Full Text] [Related]
14. MHC class I TCR engineered anti-tumor CD4 T cells: implications for cancer immunotherapy.
Chhabra A
Endocr Metab Immune Disord Drug Targets; 2009 Dec; 9(4):344-52. PubMed ID: 19807670
[TBL] [Abstract][Full Text] [Related]
15. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
[TBL] [Abstract][Full Text] [Related]
16. Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery.
Schnurr M; Chen Q; Shin A; Chen W; Toy T; Jenderek C; Green S; Miloradovic L; Drane D; Davis ID; Villadangos J; Shortman K; Maraskovsky E; Cebon J
Blood; 2005 Mar; 105(6):2465-72. PubMed ID: 15546948
[TBL] [Abstract][Full Text] [Related]
17. Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8+ T cells.
Seo MJ; Kim GR; Son YM; Yang DC; Chu H; Min TS; Jung ID; Park YM; Han SH; Yun CH
Mol Immunol; 2011 Sep; 48(15-16):1744-52. PubMed ID: 21632112
[TBL] [Abstract][Full Text] [Related]
18. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
[TBL] [Abstract][Full Text] [Related]
19. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
20. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
Duong MN; Erdes E; Hebeisen M; Rufer N
J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
